Concurrent Cisplatin or Cetuximab With Radiotherapy for HPV-positive Oropharyngeal Cancer: Medical Resource Use, Costs, and Quality-Adjusted Survival From the De-ESCALaTE HPV Trial

European Journal of Cancer - United Kingdom
doi 10.1016/j.ejca.2019.10.025
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

HPV+ Oropharyngeal Cancer and Feeding Tube Use With Chemoradiation

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2018English

Tumour-Infiltrating Lymphocytes Predict for Outcome in HPV-positive Oropharyngeal Cancer

British Journal of Cancer
Cancer ResearchOncology
2013English

Epidemiology of HPV-associated Oropharyngeal Cancer

Oral Oncology
Cancer ResearchOral SurgeryOncology
2014English

Disease Detection and Resource Use in the Safety and Control Arms of the HPV FOCAL Cervical Cancer Screening Trial

British Journal of Cancer
Cancer ResearchOncology
2016English

Significance of Negative Posttreatment 18-FDG PET/CT Imaging in Patients With P16/HPV-positive Oropharyngeal Cancer

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2018English

A 5‑year Update of Patients With HPV Positive Versus Negative Oropharyngeal Cancer After Radiochemotherapy in Austria

Wiener Klinische Wochenschrift
Medicine
2017English

Identification and Chemoresistance of Cancer Stem Cells in HPV‑negative Oropharyngeal Cancer

Oncology Letters
Cancer ResearchOncology
2019English

Concordance of Oral HPV Prevalence Between Patients With Oropharyngeal Cancer and Their Partners

Infectious Agents and Cancer
Cancer ResearchEpidemiologyOncologyInfectious Diseases
2016English

The SDF1-CXCR4-axis in HPV-positive and HPV-negative HNSCC

2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy